Home / Stocks / USNA

Usana Health Sciences (USNA, Personal Care Products) Stock Valuation & Fair Value Fairly valued

Usana Health Sciences (USNA, Personal Care Products) trades at a blended P/E of 12.9, about 18% below its historical normal valuation, with a forward growth estimate of 45.5% and a PEG of 0.28. Analysts' one-year estimates have been hit 36% of the time. Priced at its historical normal P/E of 15.8 on the same blended earnings, the 2026-09-18 close of $14.14 corresponds to about $17.30 a share. This is a valuation reference, not a price target.

Blended P/E
12.9
Normal P/E
15.8
PEG
0.28
Fwd growth
45.5%
Div yield
0.0%
RSI (14)
39.9
Neutral
Technical context
  • Price $14.04 at the 2026-09-23 close, 3.1% below the 20-day average ($14.49) and 16.3% below the 50-day ($16.77).
  • RSI (14) at 39.9.
  • 52-week range $12.86 to $28.91: the price is 51.4% below the high and 9.2% above the low.

The Street vs SeerForecast

Wall Street's mean price target for USNA is $25.00 across 1 analysts, 78.1% above the current price. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been fairly valued since 2026-07-31.

Blended P/E and rating by weekBlended P/E moved from 10.9 to 12.9 between 2026-07-31 and 2026-09-21, against a normal P/E of 15.8, with 0 rating changes over 18 recorded weeks.2026-07-31: P/E 10.9, Fairly valued (recalculated)2026-08-03: P/E 10.8, Fairly valued2026-08-07: P/E 10.8, Fairly valued (recalculated)2026-08-10: P/E 12.6, Fairly valued2026-08-14: P/E 12.6, Fairly valued (recalculated)2026-08-17: P/E 11.1, Fairly valued2026-08-21: P/E 11.1, Fairly valued (recalculated)2026-08-24: P/E 11.4, Fairly valued2026-08-27: P/E 11.4, Fairly valued (recalculated)2026-08-28: P/E 11.4, Fairly valued (recalculated)2026-08-30: P/E 11.4, Fairly valued (recalculated)2026-08-31: P/E 12.1, Fairly valued2026-09-05: P/E 12.1, Fairly valued (recalculated)2026-09-07: P/E 13.1, Fairly valued2026-09-12: P/E 13.1, Fairly valued (recalculated)2026-09-14: P/E 13.5, Fairly valued2026-09-19: P/E 13.5, Fairly valued (recalculated)2026-09-21: P/E 12.9, Fairly valued12.014.0Jul 31Aug 13Aug 26Sep 8Sep 21Normal P/E 15.8
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 10.9-31%Fairly valued
2026-08-03P/E 10.8-31%Fairly valued
2026-09-14P/E 13.5-15%Fairly valued
2026-09-21P/E 12.9-18%Fairly valued ← now

Frequently asked questions

Is Usana Health Sciences stock overvalued?

At a blended P/E of 12.9 versus its historical normal P/E of 15.8, Usana Health Sciences trades about 18% below its typical valuation, with a PEG of 0.28 on 45.5% forward growth. tickerseer currently rates it fairly valued.

What is Usana Health Sciences's fair value and PEG?

Usana Health Sciences trades at a blended P/E of 12.9 against a historical normal P/E of 15.8, a PEG of 0.28, and a forward growth estimate of 45.5%. Priced at its historical normal P/E of 15.8 on the same blended earnings, the 2026-09-18 close of $14.14 corresponds to about $17.30 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Usana Health Sciences changed?

tickerseer's rating has been fairly valued since 2026-07-31.

What is the analyst price target for Usana Health Sciences?

The mean Wall Street price target for Usana Health Sciences is $25.00 across 1 analysts, 78.1% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Personal Care Products. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.